Researchers at the University of Calgary are exploring the potential of high doses of vitamin B3 to enhance treatment outcomes for patients diagnosed with glioblastoma, a particularly aggressive form of brain cancer.
CALGARY, Alberta – In a significant development for oncology, researchers at the University of Calgary are conducting a clinical trial to assess whether high doses of vitamin B3, also known as niacin, can improve treatment outcomes for patients with glioblastoma, one of the most aggressive forms of brain cancer. This research comes at a critical time, as glioblastoma has a notoriously poor prognosis, with survival rates having stagnated for decades despite advances in medical technology and treatment protocols.
Edward Waldner, a 55-year-old participant in the trial, began experiencing debilitating fatigue and subtle mobility changes, prompting him to seek medical assistance. Following an emergency department visit, he received a devastating diagnosis: glioblastoma. “The doctor said I had a mass on my brain and needed to see an oncologist,” Waldner recounted, reflecting the shock that many patients experience upon learning of their condition.
Understanding Glioblastoma
Standard treatment for glioblastoma typically involves a triad of interventions: surgical excision of the tumor, followed by adjuvant chemotherapy and radiation therapy. Despite these measures, glioblastoma frequently recurs, and the average survival rate remains dishearteningly low. According to the American Brain Tumor Association, the median survival for glioblastoma patients hovers around 15 months, with only about 5% surviving beyond five years. This grim reality underscores the urgency of exploring new therapeutic options.
Research Objectives and Methodology
The clinical trial led by Dr. Gloria Roldan Urgoiti, an oncologist with a focus on brain cancers, and Dr. Wee Yong, a neuroscientist specializing in immune responses, seeks to investigate the potential of niacin as a complementary treatment. Both researchers are affiliated with the Hotchkiss Brain Institute and the Arnie Charbonneau Cancer Institute. The primary goal is to evaluate whether niacin can restore the function of immune cells that glioblastoma aggressively suppresses, thereby enhancing their capacity to attack malignant cells.
Initial laboratory studies conducted on murine models demonstrated that niacin treatment could significantly extend survival rates. These promising findings laid the groundwork for the current Phase I and II clinical trial, which is designed to establish the highest safe dosage of niacin and assess its potential to augment the effects of conventional chemotherapy and radiotherapy.
Preliminary Findings and Clinical Significance
As part of the trial, researchers set a critical benchmark: the continuation of the study would be contingent upon achieving a 20% improvement in progression-free survival at the six-month mark compared to historical data. Early results from a cohort of 24 participants are encouraging, indicating that 82% of patients exhibited no disease progression at the six-month follow-up. This represents a 28% improvement over previous studies, suggesting that niacin could offer a meaningful benefit in a landscape where treatment options are limited.
However, the research team remains cautious about these preliminary findings. Dr. Roldan Urgoiti emphasized, “Glioblastoma is the most aggressive brain cancer in adults. Survival of patients with this condition hasn’t changed significantly for 20 years. Anything that may help should be explored, but it requires strict protocols and safety monitoring.” This statement reflects the scientific community’s broader concern regarding the complexities of treating such a formidable disease.
Risks and Future Directions
While niacin is generally regarded as safe, researchers caution against high doses, which can lead to adverse side effects if not properly monitored. The clinical trial is conducted under strict medical supervision to safeguard participant health and wellbeing. The research team aims to complete the final analysis once enrollment reaches 48 participants, which is expected by the end of 2026 or early 2027.
For Waldner, participating in the trial has provided a sense of agency and hope amid a challenging diagnosis. “I have no problem trying to help anybody. I agreed. I want to help myself too,” he stated, encapsulating the dual motivation that drives many patients to participate in clinical research. He remains optimistic as he awaits follow-up scans, expressing gratitude each time he hears that his condition is stable.
Broader Implications for Cancer Treatment
The outcomes of this research could have far-reaching implications not only for glioblastoma treatment but also for understanding the role of vitamin B3 in cancer therapy more broadly. As researchers continue to explore the potential benefits of dietary supplements like niacin, the findings could pave the way for novel therapeutic strategies that enhance the efficacy of existing treatments.
The clinical trial is supported by the Canadian Institutes of Health Research and the Alberta Cancer Foundation, reflecting a commitment to advancing cancer research and improving patient outcomes. As the study progresses, the scientific community and patients alike will be watching closely for further developments.
Reference: “A phase I-II study of niacin in patients with newly diagnosed glioblastoma: safety and interim phase II analysis” by Gloria Roldan Urgoiti et al., published on November 28, 2025, in the Journal of Neuro-Oncology.
